EIF4EBP1 in Breast Cancer: Translational Control, Regulatory Networks, and Therapeutic Frontiers
Open Access
- 14 August 2026
- journal article
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (8)
Abstract
Eukaryotic initiation factor 4E-binding protein 1 (EIF4EBP1/4E-BP1) is a pivotal translational regulator with context-dependent roles in breast cancer pathogenesis. Its phosphorylation status, dynamically controlled by mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), and AMP-activated protein kinase (AMPK) signaling, dictates a dualistic function: hypophosphorylated EIF4EBP1 suppresses oncogenesis by sequestering eIF4E and inhibiting cap-dependent translation of pro-tumorigenic mRNAs (e.g., cyclin D1 and c-MYC), while hyperphosphorylation promotes tumor progression and therapeutic resistance. EIF4EBP1 amplification (8p11-p12) is correlated with endocrine resistance and poor prognosis. EIF4EBP1 modulates cell cycle checkpoints, metabolic adaptation under stress, and resistance to cyclin-dependent kinase (CDK) 4 and 6 inhibitors and rapalogs via feedback loops (e.g., SGK3/Akt reactivation). Emerging therapeutic strategies, such as ATP-competitive mTOR inhibitors, bisteric compounds, and agents targeting polyamine metabolism or upstream kinases, exploit the dynamics of EIF4EBP1 phosphorylation. As a biomarker, phosphorylated EIF4EBP1 levels predict tumor aggressiveness and treatment failure, positioning it as a critical node for precision oncology. Future research must address spatial heterogeneity and leverage multi-omics/AI-driven approaches.Keywords
Funding Information
- Jiangsu Higher Education Institution Innovative Research Team for Science and Technology
- Program of Jiangsu vocational college engineering technology research center
- Project of State Key Laboratory of Radiation Medicine and Protection, Soochow University (GZK1202506)
- Research Foundation of Jiangsu Commission of Health (Z2023031)
- Project of Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology (SGK1202413)
This publication has 115 references indexed in Scilit:
- Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitorsScience China Life Sciences, 2022
- Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancerCancer Medicine, 2022
- Sophoridine Derivatives Induce Apoptosis and Autophagy to Suppress the Growth of Triple‐Negative Breast Cancer through Inhibition of mTOR SignalingChemMedChem, 2021
- PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestaneJournal of Cancer Research and Clinical Oncology, 2020
- Introduction of a multicenter online database for non-metastatic breast cancer in ChinaScience China Life Sciences, 2020
- The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targetsClinical and Translational Oncology, 2014
- Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cellsApoptosis, 2014
- mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanismsBreast Cancer Research and Treatment, 2014
- Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft modelsBreast Cancer Research and Treatment, 2012
- High‐resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1Genes, Chromosomes and Cancer, 2011